Drug Monograph
Full clinical overview, indications, dosage references & safety notes.
Overview
Clofazimine (Lamprene®) is an antimycobacterial antibiotic used primarily for the treatment of infections caused by certain Mycobacterium species. In veterinary medicine, it may be used in dogs and cats as part of combination therapy for mycobacterial diseases, including feline leprosy–like infections.
Clinical experience with clofazimine in veterinary patients is limited, and most available information is derived from human medicine. Treatment of mycobacterial infections in animals typically requires long-term therapy and is commonly combined with other antimicrobials such as clarithromycin, doxycycline, or fluoroquinolones. Clofazimine is highly lipid-soluble and tends to accumulate in fatty tissues and macrophages, resulting in a prolonged persistence in the body.
Mechanism of Action (MOA): Clofazimine binds to mycobacterial DNA and interferes with bacterial growth, producing a slow bactericidal effect against susceptible organisms. It is active against several Mycobacterium species, including organisms associated with leprosy-like infections. In addition to its antimicrobial activity, the drug may also have anti-inflammatory and immunomodulatory effects, although the exact mechanisms are not fully understood.
Indications
Clofazimine may be used in dogs and cats for the treatment of infections caused by certain Mycobacterium species. In veterinary medicine, the drug is most commonly used as part of combination antimicrobial therapy because mycobacterial infections often require prolonged multidrug treatment.
- Mycobacterial infections: Used for infections caused by susceptible Mycobacterium species, including atypical or non-tuberculous mycobacterial diseases affecting the skin or soft tissues.
- Feline leprosy–like infections: Clofazimine may be included in treatment protocols for feline mycobacterial infections associated with nodular or granulomatous skin lesions.
- Combination antimicrobial therapy: Commonly administered with other antimicrobials such as clarithromycin, doxycycline, or fluoroquinolones to improve treatment success in chronic mycobacterial infections.
Dosage (Reference)
Dog
In dogs, clofazimine is used primarily for the management of mycobacterial infections. Treatment usually requires long-term therapy and the drug is typically administered as part of combination antimicrobial protocols.
| Clinical use | Route | Dose | Frequency | Notes |
|---|---|---|---|---|
| Mycobacterial infections | PO | 4–8 mg/kg | Every 24 hours | Long-term therapy typically required for effective disease control. |
• Treatment duration is typically prolonged, often lasting 2–6 months depending on clinical response.
• Clofazimine is usually used as part of combination therapy with other antimicrobials such as fluoroquinolones or clarithromycin.
• Monitor treatment response and potential adverse effects during long-term therapy.
Cat
In cats, clofazimine may be used in the management of feline mycobacterial infections, including leprosy-like disease. Therapy is typically prolonged and commonly combined with other antimicrobial agents.
| Clinical use | Route | Dose | Frequency | Notes |
|---|---|---|---|---|
| Mycobacterial infections (including feline leprosy-like disease) | PO | 4–8 mg/kg | Every 24 hours | Used as part of multidrug therapy for chronic mycobacterial infections. |
• Treatment usually requires long-term administration (2–6 months).
• Clofazimine is generally combined with other antimicrobials such as clarithromycin, doxycycline, or fluoroquinolones.
• Clinical response should be monitored during therapy to guide treatment duration.
Warnings & Precautions
Clofazimine should be used cautiously in dogs and cats because clinical experience with this drug in veterinary medicine is limited. Careful monitoring during treatment is recommended, especially when long-term therapy is required for mycobacterial infections.
- Limited veterinary data: Published clinical experience in dogs and cats is very limited, and much of the available information is extrapolated from human medicine.
- Gastrointestinal disease: Use cautiously in patients with pre-existing gastrointestinal conditions such as diarrhea or abdominal pain, as the drug may worsen GI signs.
- Hepatic or renal impairment: Clofazimine should be used cautiously in animals with liver or kidney dysfunction, and monitoring of hepatic and renal function is recommended during treatment.
- Tissue and fluid discoloration: The drug is a phenazine dye and may cause discoloration of skin, eyes, and body fluids. This change may persist for months after treatment is discontinued.
- Long-term therapy: Treatment for mycobacterial infections is typically prolonged, and animals should be monitored for adverse effects and clinical response throughout therapy.
Drug Interactions
Several drug interactions with clofazimine have been reported or proposed based mainly on human data. While their clinical significance in veterinary patients is not fully established, caution and monitoring are recommended when these medications are used together.
- Antacids: May reduce gastrointestinal absorption of clofazimine and decrease systemic drug concentrations. Separate administration times when possible.
- Dapsone: Some evidence suggests that dapsone may reduce the anti-inflammatory effects of clofazimine; the clinical importance of this interaction is uncertain.
- Isoniazid: May alter clofazimine distribution by decreasing concentrations in the skin and increasing levels in plasma and urine; the clinical significance remains unclear.
- QT-prolonging drugs (e.g., amiodarone, cisapride, quinidine, sotalol): Concurrent administration may increase the risk of QT interval prolongation and serious cardiac arrhythmias.
Side Effects & Overdose
Side Effects
Clinical experience with clofazimine in dogs and cats is limited, and most information regarding adverse effects is derived from human medicine. The most commonly reported effects involve gastrointestinal irritation and discoloration of body tissues and fluids due to the drug’s dye properties.
- Skin and tissue discoloration: Clofazimine commonly causes pink, red, or brownish discoloration of the skin, eyes, and body fluids. This effect may persist for months after treatment is discontinued.
- Gastrointestinal signs: Abdominal discomfort, nausea, vomiting, or diarrhea may occur and are considered dose-related.
- Photosensitivity (rare): A photosensitization reaction has been reported in a cat receiving clofazimine therapy.
- Hepatotoxicity: Liver toxicity has been reported in a dog receiving clofazimine in combination with rifampin.
Overdose
Information regarding clofazimine overdose in dogs and cats is very limited. Available experimental data suggest that the drug has a relatively wide safety margin, but excessive doses may increase the likelihood of gastrointestinal toxicity and systemic adverse effects.
- Gastrointestinal toxicity: Overdose may result in severe gastrointestinal irritation including vomiting, diarrhea, and abdominal pain.
- Supportive management: Treatment is primarily supportive and may include gastrointestinal decontamination when appropriate and monitoring for adverse clinical signs.
- Consultation recommended: Veterinary poison consultation is recommended when significant overdose is suspected.
Key Notes
Practical clinical considerations that may assist veterinarians when using clofazimine for the management of mycobacterial infections in dogs and cats:
- Very long tissue persistence: Clofazimine accumulates extensively in lipid-rich tissues and macrophages, resulting in an extremely long tissue half-life that can exceed several weeks.
- Slow antimicrobial activity: The drug acts slowly against mycobacteria, and clinical improvement in chronic infections may take weeks before noticeable response occurs.
- Administration with food: Oral absorption improves when the medication is given with food, which may help optimize systemic drug exposure.
- Limited antimicrobial spectrum: Clofazimine is primarily active against mycobacteria and has little to no activity against most other bacterial, fungal, or protozoal pathogens.
- Difficult dosing in small patients: The commercially available capsule strength may make accurate dosing difficult in small dogs or cats, and compounded formulations may sometimes be required.
- Restricted availability: Access to clofazimine may be limited in some regions because its use is prioritized for human treatment of leprosy.
Calculate Any Dose Instantly
Use our smart dose calculator to get accurate dosing for 500+ veterinary drugs — adjusted for species, weight, and route.
